Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study
Eurocine Vaccines today announced that Immunose™ FLU, a quadrivalent influenza vaccine candidate showed good safety in a clinical phase I/II study. Immunose™ FLU is a novelRead…
Eurocine Vaccines has completed dosing in phase I/II clinical study with nasal influenza vaccine candidate Immunose™ FLU
Eurocine Vaccines today announced that the last dose has been administered in the ongoing phase I/II clinical study of Immunose™ FLU, a quadrivalent influenza vaccineRead…
Eurocine Vaccines has completed dosing in phase I/II clinical study with nasal influenza vaccine candidate Immunose™ FLU
“The study is conducted at two clinics in Sweden, and we are very pleased with the rapid enrollment,” said Dr. Marie Olliver, Director of Clinical Development.Read…
Eurocine Vaccines announces initiation of clinical study of the nasal influenza vaccine candidate Immunose™ FLU
Eurocine Vaccines today announced the start of a phase I/II clinical study of the quadrivalent influenza vaccine candidate Immunose™ FLU, a novel nose drop formulationRead…
Eurocine Vaccines announces initiation of clinical study of the nasal influenza vaccine candidate Immunose™ FLU
“We are very pleased that our nasal influenza vaccine candidate, Immunose™ FLU, has entered the clinical development stage,” said Dr. Anna-Karin Maltais, Chief Scientific Officer.Read…
The Spirit and Vision of Eurocine Vaccines – Board Directors in Interview
While the team of Eurocine Vaccines is working intensely with the upcoming clinical trial and recently represented the company in Japan, the board directors shareRead…
Eurocine Vaccines receives the Nordic Stars Award 2016
Eurocine Vaccines received the Nordic Stars Award 2016 at the Nordic Life Science Days in Stockholm. – We were thrilled to bring our recently approvedRead…
Eurocine Vaccines receives the Nordic Stars Award 2016
Nordic Stars Award is a prize highlighting early and exciting Nordic life science companies. It was established in 2013 with the purpose of rewarding particularlyRead…